Chunhuan Lao1, Marion Kuper-Hommel2, Mark Elwood3, Ian Campbell4,5, Melissa Edwards4, Ross Lawrenson6,7. 1. Waikato Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand. chunhuan.lao@waikato.ac.nz. 2. Medical Oncology, Waikato District Health Board, Hamilton, New Zealand. 3. School of Population Health, The University of Auckland, Auckland, New Zealand. 4. School of Medicine, The University of Auckland, Auckland, New Zealand. 5. General Surgery, Waikato District Health Board, Hamilton, New Zealand. 6. Waikato Medical Research Centre, The University of Waikato, Private Bag 3105, Hamilton, 3240, New Zealand. 7. Strategy and Funding, Waikato District Health Board, Hamilton, New Zealand.
Abstract
BACKGROUND: We aim to examine the characteristics and survival of patients with de novo metastatic breast cancer (dnMBC) and recurrent metastatic breast cancer (rMBC) in New Zealand. METHODS: This study included women diagnosed with dnMBC and women who developed rMBC between 2010 and 2017. The Kaplan-Meier method was used to examine cancer-specific survival. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) of cancer-specific mortality by ethnicity, age, year of diagnosis, socioeconomic deprivation, site of metastases, number of metastatic sites, biomarker subtype and MBC subgroup. RESULTS: We included 2177 MBC patients (667 dnMBC and 1510 rMBC). The median survival of dn MBC patients was 26 months compared to 18 months for rMBC. There were no differences in breast-cancer specific mortality by ethnicity or socioeconomic deprivation. The adjusted HR for patients with visceral metastases compared to patients with non-visceral metastases was 1.41, and the adjusted HR for triple negative disease compared to Luminal A disease was 2.24. Compared to dnMBC, the adjusted HRs for rMBC patients with a metastatic-free interval of < 2 years, 2-4 years, 5-7 year and 8 + years were 1.81, 1.47, 1.08 and 0.82, respectively. CONCLUSIONS: The survival for patients with MBC in New Zealand is very similar to other developed countries. Patients with dnMBC had a much better prognosis than those with recurrent disease. Patients with triple negative disease or non-luminal HER2 positive disease had the worst prognosis. The prognosis for patient with rMBC improved the longer the time from diagnosis to the development of metastases.
BACKGROUND: We aim to examine the characteristics and survival of patients with de novo metastatic breast cancer (dnMBC) and recurrent metastatic breast cancer (rMBC) in New Zealand. METHODS: This study included women diagnosed with dnMBC and women who developed rMBC between 2010 and 2017. The Kaplan-Meier method was used to examine cancer-specific survival. Cox proportional hazards regression was used to estimate the adjusted hazard ratio (HR) of cancer-specific mortality by ethnicity, age, year of diagnosis, socioeconomic deprivation, site of metastases, number of metastatic sites, biomarker subtype and MBC subgroup. RESULTS: We included 2177 MBCpatients (667 dnMBC and 1510 rMBC). The median survival of dn MBCpatients was 26 months compared to 18 months for rMBC. There were no differences in breast-cancer specific mortality by ethnicity or socioeconomic deprivation. The adjusted HR for patients with visceral metastases compared to patients with non-visceral metastases was 1.41, and the adjusted HR for triple negative disease compared to Luminal A disease was 2.24. Compared to dnMBC, the adjusted HRs for rMBCpatients with a metastatic-free interval of < 2 years, 2-4 years, 5-7 year and 8 + years were 1.81, 1.47, 1.08 and 0.82, respectively. CONCLUSIONS: The survival for patients with MBC in New Zealand is very similar to other developed countries. Patients with dnMBC had a much better prognosis than those with recurrent disease. Patients with triple negative disease or non-luminalHER2 positive disease had the worst prognosis. The prognosis for patient with rMBC improved the longer the time from diagnosis to the development of metastases.
Entities:
Keywords:
Biomarker subtype; De novo metastatic breast cancer; Metastatic-free interval; Recurrent metastatic breast cancer; Site of metastases; Survival
Authors: Jenny Chang; Gary M Clark; D Craig Allred; Syed Mohsin; Gary Chamness; Richard M Elledge Journal: Cancer Date: 2003-02-01 Impact factor: 6.860
Authors: Ross Lawrenson; Chunhuan Lao; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne; Mark Elwood; Diana Sarfati; Marion Kuper-Hommel Journal: N Z Med J Date: 2018-05-18
Authors: Ross Lawrenson; Chunhuan Lao; Ian Campbell; Vernon Harvey; Sanjeewa Seneviratne; Melissa Edwards; Mark Elwood; Nina Scott; Jacquie Kidd; Diana Sarfati; Marion Kuper-Hommel Journal: Cancer Causes Control Date: 2017-10-13 Impact factor: 2.506
Authors: D J A Lobbezoo; R J W van Kampen; A C Voogd; M W Dercksen; F van den Berkmortel; T J Smilde; A J van de Wouw; F P J Peters; J M G H van Riel; N A J B Peters; M de Boer; P G M Peer; V C G Tjan-Heijnen Journal: Br J Cancer Date: 2015-04-16 Impact factor: 7.640
Authors: Sanjeewa Seneviratne; Ross Lawrenson; Vernon Harvey; Reena Ramsaroop; Mark Elwood; Nina Scott; Diana Sarfati; Ian Campbell Journal: BMC Cancer Date: 2016-02-19 Impact factor: 4.430
Authors: Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Debra P Ritzwoller Journal: JNCI Cancer Spectr Date: 2018-06-28